Drug Profile
Research programme: cancer immunotherapeutics - Akamis Bio
Alternative Names: AbEnAds; anti-human VEGF armed EnAd; anti-PDL1 AbEnAds; NG 345; NG 347; NG 600; NG aEpCAM; NG aFAP; NG-600 seriesLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator PsiOxus Therapeutics
- Developer Akamis Bio
- Class Antibodies; Antineoplastics; Bispecific antibodies; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Epithelial cell adhesion molecule inhibitors; Fibroblast activation protein antagonists; Gene transference; Immunomodulators; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors; Vascular endothelial growth factors modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (Intratumoural, Injection)
- 05 Jan 2023 PsiOxus Therapeutics is now called Akamis Bio
- 10 Apr 2021 Preclinical pharmacodynamic presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)